Medaus Recalls Testosterone Cypionate Vials Due to Sterility Concerns
Medaus, Inc. is recalling Testosterone Cypionate vials because the company cannot guarantee the product is sterile. The recall covers vials distributed in the U.S., Japan, and New Zealand.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classification is FDA Class II. Per the rubric, FDA Class II recalls involving significant injury/property-damage reports or hospitalization are Severe (4). While specific injury reports are not detailed in the provided text, the 'Lack of Assurance of Sterility' for an injectable drug represents a significant risk of serious adverse health consequences (infection/sepsis), aligning with the Severe criteria for Class II recalls where the hazard is significant.
Plain-English summary
Medaus, Inc. is recalling specific lots of Testosterone Cypionate 200 mg/mL with preservative (benzyl alcohol 2%) in 1 mL, 2 mL, 3 mL, 4 mL, and 5 mL vials. The recall was initiated due to a lack of assurance of sterility for the affected product.
The affected product was distributed nationwide in the United States, as well as in Japan and New Zealand. The recall includes approximately 8,000 mL of product in vials. Specific lot numbers and expiration dates are listed in the structured product information provided by the FDA.
Consumers and healthcare providers should stop using the recalled product and contact Medaus, Inc. or their healthcare provider for further instructions. The FDA has classified this recall as Class II, indicating that use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences.
The recalled product
- Product
- TESTOSTERONE CYP 200 MG/ML W/PRES (BENZYL ETOH 2%), In a) 1ML Vials, b) 2ML Vials, c) 3ML Vials, d) 4ML, and e) 5ML Vials, MEDAUS PHARMACY
- Manufacturer
- Medaus, Inc.
- Category
- Drug — Injectable Steroid
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (19)
- a) Lot #151210-5
- BUD: 06/07/16
- Lot #160204-31
- BUD: 08/02/16
- Lot #160107-8
- BUD: 07/05/16
- Lot #160303-47
- BUD: 08/30/16. b) Lot #151210-5
- BUD: 08/30/16. c) Lot #151207-8
- BUD: 06/04/16
- BUD: 08/30/16
- Lot #151210-5
- Lot #160106-34
- BUD: 07/04/16
- Lot#160208-22
- BUD: 08/06/16. d) Lot #151210-5
- BUD: 08/30/16. e) Lot #151210-5
- BUD: 08/02/16
- BUD: 08/30/16.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 88 recalled by Medaus, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 88 products in this recall →Related recalls
Same manufacturer · Medaus, Inc.
See all →- SevereMedaus Recalls Testosterone Cypionate Vials Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls Testosterone Cypionate Vials Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls Taurine Vials Due to Lack of Sterility Assurance
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls Lipo-Injection Vials Due to Sterility Assurance Concerns
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls B-Complex Vials Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
Same hazard · sterility
See all →- SevereRegeneron Recalls Libtayo Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-08-26
- SeverePrestige Recalls Clear Eyes Maximum Itchy Eye Relief Due to Sterility Concerns
FDA (Drugs) · 2026-08-19
- SevereROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- HighROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- SevereFDA Recalls ROHTO OPTIC GLOW Eye Drops Over Sterility Concerns
FDA (Drugs) · 2026-07-29